Alembic Pharmaceuticals Ltd
About
Alembic Pharmaceuticals manufactures Indian formulations, active pharmaceutical ingredients (APIs), and international generics around the world. The company was originally a part of Alembic Group until it demerged in 2010 to become a standalone pharmaceutical enterprise. Out of its 185+ brands that cater to more than 200,000 doctors, 3 are in the top 300 brands in India. Alembic’s products are used in gastroenterology, ophthalmology, orthopaedics, anti-inflammatories, nephrology, cardiology, gynaecology, and more. Its APIs are produced in 3 manufacturing facilities in Gujarat, while its formulations are made in 6 facilities, 1 of which is in Sikkim. Under the leadership of Chirayu Amin, Alembic also operates 3 R&D facilities for international generics in Gujarat, Telangana, and New Jersey.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 6400 14.8% | 5577 3.2% | 5405 -4.8% | 5674 17.7% | 4821 19.5% | 4036 26.9% | 3180 0.1% | 3177 -2.8% | 3269 53.2% | 2133 11.8% | 1908 26.9% | 1503 -2.6% | 1543 27.4% | 1211 - |
| Net Operating Income (INR Cr) | 6229 10.19% | 5653 6.54% | 5306 -1.62% | 5393 17.10% | 4606 17.06% | 3935 25.68% | 3131 0.83% | 3105 -1.92% | 3166 53.98% | 2056 10.35% | 1863 22.55% | 1520 3.75% | 1465 21.91% | 1202 0.00% |
| Profit (INR Cr) | 616 80.1% | 342 -34.4% | 521 -54.6% | 1147 38.3% | 829 41.8% | 584 41.6% | 413 2.4% | 403 -44.0% | 720 154.5% | 283 20.1% | 236 42.5% | 165 27.0% | 130 52.4% | 85 - |
| Assets (INR Cr) | 5441 4.7% | 5199 -14.1% | 6050 5.5% | 5736 12.8% | 5086 30.5% | 3898 31.3% | 2969 45.0% | 2048 16.9% | 1752 49.7% | 1170 45.5% | 804 13.5% | 709 -7.4% | 765 19.3% | 642 - |
| Net Worth (INR Cr) | 4818 10.2% | 4370 -16.6% | 5238 3.4% | 5067 57.4% | 3219 18.4% | 2719 22.5% | 2220 16.7% | 1902 19.1% | 1597 80.6% | 885 31.0% | 676 34.3% | 503 27.3% | 395 46.3% | 270 0.0% |
| Employee Cost (INR Cr) | 1446 23.7% | 1169 3.2% | 1133 7.8% | 1051 16.0% | 906 21.4% | 747 19.9% | 623 11.5% | 559 18.2% | 473 54.1% | 307 24.2% | 247 27.5% | 194 15.0% | 168 12.9% | 149 - |
| Interest Cost (INR Cr) | 56 | 50 | 18 | 16 | 27 | 18 | 3 | 5 | 5 | 4 | 10 | 15 | 38 | 28 |
| Cash & Bank Balance (INR Cr) | 127 | 82 | 69 | 106 | 81 | 206 | 90 | 160 | 451 | 27 | 24 | 16 | 47 | 6 |
| Total Debt (INR Cr) | 513 | 722 | 717 | 584 | 1747 | 1128 | 708 | 89 | 114 | 264 | 109 | 187 | 353 | 328 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 9.6% | 6.1% | 9.6% | 20.2% | 17.2% | 14.5% | 13.0% | 12.7% | 22.0% | 13.3% | 12.4% | 11.0% | 8.4% | 7.1% |
| Profit As % Of Assets | 11.3% | 6.6% | 8.6% | 20.0% | 16.3% | 15.0% | 13.9% | 19.7% | 41.1% | 24.2% | 29.3% | 23.3% | 17.0% | 13.3% |
| Profit As % Of Networth | 12.8% | 7.8% | 10.0% | 22.6% | 25.7% | 21.5% | 18.6% | 21.2% | 45.1% | 32.0% | 34.9% | 32.9% | 33.0% | 31.6% |
| Interest Cost to EBITDA % | 6.0% | 7.4% | 2.0% | 1.1% | 2.3% | 2.1% | 0.5% | 0.9% | 0.5% | 1.0% | 2.9% | 5.8% | 17.1% | 17.2% |
| Debt to Equity Ratio | 0.11 | 0.17 | 0.14 | 0.12 | 0.54 | 0.42 | 0.32 | 0.05 | 0.07 | 0.30 | 0.16 | 0.37 | 0.89 | 1.21 |
| RONW | 13.4% | 7.1% | 10.1% | 26.9% | 27.0% | 24.0% | 20.4% | 23.3% | 58.0% | 36.2% | 40.0% | 36.8% | 39.1% | 38.0% |
| ROCE | 12.9% | 7.2% | 10.9% | 25.5% | 22.8% | 22.4% | 21.7% | 28.1% | 64.4% | 36.8% | 42.4% | 30.0% | 28.2% | 25.1% |